Axsome Therapeutics Stock Forecast, Price & News

Axsome Therapeutics (NASDAQ:AXSM) Frequently Asked Questions

Is Axsome Therapeutics a buy right now?

12 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Axsome Therapeutics in the last year. There are currently 1 hold rating and 11 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Axsome Therapeutics stock.
View analyst ratings for Axsome Therapeutics or view top-rated stocks.

How has Axsome Therapeutics' stock price been impacted by Coronavirus?

Axsome Therapeutics' stock was trading at $73.65 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, AXSM shares have decreased by 56.2% and is now trading at $32.24.
View which stocks have been most impacted by COVID-19.

When is Axsome Therapeutics' next earnings date?

Axsome Therapeutics is scheduled to release its next quarterly earnings announcement on Monday, March 7th 2022.
View our earnings forecast for Axsome Therapeutics.

How were Axsome Therapeutics' earnings last quarter?

Axsome Therapeutics, Inc. (NASDAQ:AXSM) announced its quarterly earnings results on Monday, November, 8th. The company reported ($0.93) EPS for the quarter, beating the Zacks' consensus estimate of ($0.95) by $0.02. During the same quarter in the previous year, the company earned ($0.58) earnings per share.
View Axsome Therapeutics' earnings history.

What price target have analysts set for AXSM?

12 equities research analysts have issued 12 month price targets for Axsome Therapeutics' stock. Their forecasts range from $34.00 to $180.00. On average, they expect Axsome Therapeutics' share price to reach $100.28 in the next twelve months. This suggests a possible upside of 211.0% from the stock's current price.
View analysts' price targets for Axsome Therapeutics or view top-rated stocks among Wall Street analysts.

What are Wall Street analysts saying about Axsome Therapeutics stock?

Here are some recent quotes from research analysts about Axsome Therapeutics stock:

• 1. According to Zacks Investment Research, "Axsome has submitted a regulatory filing in the United States for AXS-05 to treat major depressive disorder. A decision for the same is expected on Aug 22, 2021. Also, a similar filing for AXS-07 as an acute treatment of migraine is expected to be filed in second-quarter 2021. If both candidates are approved, the company can have two marketed products in its portfolio. The company’s other pipeline candidates, which are being developed for various CNS indications, are progressing well. However, due to lack of a marketed product, Axsome is yet to generate revenues. Dearth of collaboration contracts remains a woe. Thus, any developmental delay in the pipeline or any regulatory setback will hurt the stock. Loss estimates has narrowed ahead of Q2 earnings. Axsome has a mixed record of earnings surprise in the recent quarters." (8/4/2021)
• 2. Berenberg Bank analysts commented, " (6/10/2021)

Who are Axsome Therapeutics' key executives?

Axsome Therapeutics' management team includes the following people:

• Herriott Tabuteau, Chairman, President & Chief Executive Officer
• Mark L. Jacobson, Chief Operating Officer
• Nick Pizzie, Chief Financial & Accounting Officer (LinkedIn Profile)
• Joseph Debrah-Afful, Director of Finance
• Amanda Jones, Senior Vice President-Clinical Development

Who are some of Axsome Therapeutics' key competitors?

Some companies that are related to Axsome Therapeutics include Cerevel Therapeutics (CERE), Perrigo (PRGO), I-Mab (IMAB), Mawson Infrastructure Group (WIZP), Allakos (ALLK), Arvinas (ARVN), Apellis Pharmaceuticals (APLS), Karuna Therapeutics (KRTX), Ionis Pharmaceuticals (IONS), Alkermes (ALKS), Zentalis Pharmaceuticals (ZNTL), 23andMe (ME), Arena Pharmaceuticals (ARNA), ACADIA Pharmaceuticals (ACAD) and Cytokinetics (CYTK).
View all of AXSM's competitors.

What other stocks do shareholders of Axsome Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Axsome Therapeutics investors own include Inovio Pharmaceuticals (INO), NVIDIA (NVDA), Dicerna Pharmaceuticals (DRNA), Amarin (AMRN), Sarepta Therapeutics (SRPT), Micron Technology (MU), Pfizer (PFE), AbbVie (ABBV), Alibaba Group (BABA) and Bristol-Myers Squibb (BMY).

When did Axsome Therapeutics IPO?

(AXSM) raised $52 million in an initial public offering (IPO) on Thursday, November 19th 2015. The company issued 4,300,000 shares at a price of $11.00-$13.00 per share. Ladenburg Thalmann and Cantor Fitzgerald & Co. acted as the underwriters for the IPO and Brean Capital was co-manager.

What is Axsome Therapeutics' stock symbol?

Axsome Therapeutics trades on the NASDAQ under the ticker symbol "AXSM."

Who are Axsome Therapeutics' major shareholders?

Axsome Therapeutics' stock is owned by a variety of institutional and retail investors. Top institutional investors include BlackRock Inc. (5.49%), Alethea Capital Management LLC (3.01%), Bellevue Group AG (2.00%), Geode Capital Management LLC (1.30%), Citadel Advisors LLC (0.00%) and Morgan Stanley (0.97%). Company insiders that own Axsome Therapeutics stock include Mark Coleman, Mark E Saad, Nick Pizzie and Roger Jeffs.
View institutional ownership trends for Axsome Therapeutics.

Which institutional investors are selling Axsome Therapeutics stock?

AXSM stock was sold by a variety of institutional investors in the last quarter, including Perceptive Advisors LLC, Jane Street Group LLC, Invesco Ltd., BlackRock Inc., Peregrine Capital Management LLC, Two Sigma Advisers LP, Squarepoint Ops LLC, and Principal Financial Group Inc..
View insider buying and selling activity for Axsome Therapeutics or view top insider-selling stocks.

Which institutional investors are buying Axsome Therapeutics stock?

AXSM stock was bought by a variety of institutional investors in the last quarter, including Bellevue Group AG, New York State Teachers Retirement System, Millennium Management LLC, Voloridge Investment Management LLC, Citadel Advisors LLC, Caption Management LLC, Alethea Capital Management LLC, and Morgan Jess S & Co. Inc.. Company insiders that have bought Axsome Therapeutics stock in the last two years include Mark Coleman, Mark E Saad, Nick Pizzie, and Roger Jeffs.
View insider buying and selling activity for Axsome Therapeutics or or view top insider-buying stocks.

How do I buy shares of Axsome Therapeutics?

Shares of AXSM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Axsome Therapeutics' stock price today?

One share of AXSM stock can currently be purchased for approximately $32.24.

How much money does Axsome Therapeutics make?

Axsome Therapeutics has a market capitalization of $1.22 billion. The company earns $-102.90 million in net income (profit) each year or ($3.35) on an earnings per share basis.

How many employees does Axsome Therapeutics have?

Axsome Therapeutics employs 60 workers across the globe.

What is Axsome Therapeutics' official website?

The official website for Axsome Therapeutics is axsome.com.

Where are Axsome Therapeutics' headquarters?

Axsome Therapeutics is headquartered at 200 BROADWAY 3RD FLOOR, NEW YORK NY, 10038.

How can I contact Axsome Therapeutics?

Axsome Therapeutics' mailing address is 200 BROADWAY 3RD FLOOR, NEW YORK NY, 10038. The company can be reached via phone at (212) 332-3241 or via fax at 212-320-0245.